AU2002220734A1 - Production of recombinant bmp-2 - Google Patents

Production of recombinant bmp-2

Info

Publication number
AU2002220734A1
AU2002220734A1 AU2002220734A AU2073402A AU2002220734A1 AU 2002220734 A1 AU2002220734 A1 AU 2002220734A1 AU 2002220734 A AU2002220734 A AU 2002220734A AU 2073402 A AU2073402 A AU 2073402A AU 2002220734 A1 AU2002220734 A1 AU 2002220734A1
Authority
AU
Australia
Prior art keywords
protein
tgf
inclusion bodies
beta superfamily
mature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002220734A
Inventor
Gerhard Herr
Frank Hillger
Rainer Rudolph
Elisabeth Schwarz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Navigo Proteins GmbH
Original Assignee
Scil Proteins GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scil Proteins GmbH filed Critical Scil Proteins GmbH
Publication of AU2002220734A1 publication Critical patent/AU2002220734A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

In order to recombinantly prepare a biologically active protein of the TGF-beta superfamily, a protein, whose amino terminus consists of the pro sequence of a protein of the TGF-beta superfamily, or parts thereof, to which the mature domain of this protein or of another protein of TGF-beta superfamily which exhibits at least 35% homology with mature BMP-2 is attached, is expressed in prokaryotes under conditions in which at least a part of the protein is obtained in the form of inclusion bodies, the inclusion bodies are isolated and solubilized under denaturing conditions, the denatured, monomeric and biologically inactive protein which has been solubilized from the inclusion bodies is renatured, with folding and dimerization to give the soluble, biologically active conformation and, where appropriate, after the renaturation, the mature protein is released proteolytically from its pro form.
AU2002220734A 2000-11-29 2001-11-27 Production of recombinant bmp-2 Abandoned AU2002220734A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10059336.4 2000-11-29
DE10059336A DE10059336A1 (en) 2000-11-29 2000-11-29 Production of recombinant BMP-2
PCT/EP2001/013840 WO2002044203A2 (en) 2000-11-29 2001-11-27 Production of recombinant bmp-2

Publications (1)

Publication Number Publication Date
AU2002220734A1 true AU2002220734A1 (en) 2002-06-11

Family

ID=7665158

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002220734A Abandoned AU2002220734A1 (en) 2000-11-29 2001-11-27 Production of recombinant bmp-2

Country Status (8)

Country Link
US (1) US7354901B2 (en)
EP (1) EP1339744B1 (en)
JP (1) JP2004514441A (en)
CN (1) CN100469790C (en)
AT (1) ATE455126T1 (en)
AU (1) AU2002220734A1 (en)
DE (2) DE10059336A1 (en)
WO (1) WO2002044203A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2495222A1 (en) * 2002-08-13 2004-02-19 Wyeth Peptides as solubilizing excipients for transforming growth factor ss proteins
US20050282713A1 (en) * 2004-03-31 2005-12-22 Matsushita Electric Industrial Co., Ltd. Hydrodynamic bearing device and spindle motor using the same
CN1824773B (en) * 2005-02-25 2010-06-23 东北师范大学遗传与细胞研究所 Human testicle specificity protein 50 gene expression regulator screening system and method of screening its gene expression regulator
WO2007052096A2 (en) * 2005-06-29 2007-05-10 Cameron Malcolm Lang Clokie Production of bone morphogenic proteins (bmps) in transgenic mammals
CN100410371C (en) * 2006-05-13 2008-08-13 暨南大学 Expression method of recombination human bone formation protein-2
US8114428B2 (en) * 2007-03-08 2012-02-14 Sbf Synthetic Bone Factory Gmbh Methods for manufacturing a composition for treating bone and/or cartilage defects
EP2167665A4 (en) * 2007-05-25 2010-12-29 Induce Biolog Inc A method of enhancing recombinant protein production
CA2653866A1 (en) * 2008-07-03 2010-01-03 Induce Biologics Inc. Use of immobilized antagonists for enhancing growth factor containing bioimplant effectiveness
JPWO2010098421A1 (en) * 2009-02-27 2012-09-06 株式会社オステオファーマ Recombinant human bone morphogenetic protein with improved storage stability
US8825859B2 (en) * 2009-12-23 2014-09-02 Citrix Systems, Inc. System and methods for mixed mode of IPv6 and IPv4 DNS of global server load balancing
US9098335B2 (en) * 2009-12-23 2015-08-04 Citrix Systems, Inc. Systems and methods for managing spillover limits in a multi-core system
WO2011079182A2 (en) 2009-12-23 2011-06-30 Citrix Systems, Inc. Systems and methods for managing ports for rtsp across cores in a multi-core system
US9757330B2 (en) 2013-10-18 2017-09-12 Industrial Technology Research Institute Recipe for in-situ gel, and implant, drug delivery system formed thereby
CN104163865A (en) * 2014-07-01 2014-11-26 杭州瑞固生物技术有限公司 Optimized DNA sequences of recombinant human bone morphogenetic protein-2 and coded protein thereof
CN104961820B (en) * 2015-06-02 2018-07-20 烟台正海生物科技股份有限公司 A kind of recycling chromatography refolding method of recombinant human bone morphogenesis protein-2
CN111574583B (en) * 2020-04-10 2021-06-25 上海海路生物技术有限公司 Protein renaturation reagent and its application
CN114133444A (en) * 2021-11-25 2022-03-04 中国人民解放军总医院第四医学中心 Preparation method of human BMP2 and analogues thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013649A (en) * 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
JPH04218000A (en) * 1990-02-13 1992-08-07 Kirin Amgen Inc Modified polypeptide
US6395883B1 (en) * 1991-03-11 2002-05-28 Curis, Inc. Soluble morphogenic protein complex compositions of matter
US5674844A (en) * 1991-03-11 1997-10-07 Creative Biomolecules, Inc. Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
EP1637156A1 (en) * 1991-08-30 2006-03-22 Curis, Inc. Systemic administration of osteogenic proteins in the treatment of metabolic bone diseases
US6352972B1 (en) * 1995-06-06 2002-03-05 Marcel E. Nimni Bone morphogenetic proteins and their use in bone growth
CA2224867A1 (en) * 1995-06-22 1997-01-09 Eli Lilly And Company Obesity protein intermediates and their preparation and use
CN1165189A (en) * 1996-05-10 1997-11-19 中国人民解放军第四军医大学 Human bone morphogenetic protein-3 possessing induced activity prepared by Bacillus coli expression
AU3269399A (en) * 1999-03-22 2000-10-09 Universitat Zurich Transforming growth factor (tfg) beta superfamily antagonists

Also Published As

Publication number Publication date
JP2004514441A (en) 2004-05-20
US7354901B2 (en) 2008-04-08
ATE455126T1 (en) 2010-01-15
DE50115313D1 (en) 2010-03-04
EP1339744B1 (en) 2010-01-13
EP1339744A2 (en) 2003-09-03
DE10059336A1 (en) 2002-06-13
CN1484651A (en) 2004-03-24
WO2002044203A2 (en) 2002-06-06
CN100469790C (en) 2009-03-18
WO2002044203A3 (en) 2003-04-10
US20040018595A1 (en) 2004-01-29

Similar Documents

Publication Publication Date Title
AU2002220734A1 (en) Production of recombinant bmp-2
EP0345660B1 (en) Stabilized fgf composition and production thereof
EP2253645A3 (en) Factor VIII Polypeptide
AU4975699A (en) High pressure refolding of protein aggregates and inclusion bodies
WO2005099769A3 (en) Novel g-csf conjugates
CA2397773A1 (en) Universal procedure for refolding recombinant proteins
EP2298331A3 (en) Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
ATE477020T1 (en) PREVENTION AND REDUCTION OF ISCHEMIA
CA2380569A1 (en) Chimeric polypeptides, method for production and uses thereof
WO2005017149A8 (en) Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
WO2005115306A3 (en) Keratin-binding polypeptides
DE69820885D1 (en) PEPTIDE SEQUENCES AS HINGE REGIONS IN PROTEINS LIKE IMMUNGLOBULIN FRAGMENTS AND THEIR USE IN HEALING CUSTOMERS
HK1150618A1 (en) Homogeneous preparations of il-29 il-29
DE60229836D1 (en) HIGHLY SOY PROTEIN OF HIGH MOLECULAR WEIGHT
WO2002060468A3 (en) Antiviral activities of primate theta defensins and mammalian cathelicidins
CA2257122A1 (en) Method of activating denatured protein
ES2138973T3 (en) MUTEINS OF IL-6 FREE OF CYSTEINE.
ATE481420T1 (en) IL-21 DERIVATIVES
DE602004028266D1 (en) ANGIOGENIC PEPTIDES AND ITS USES
IL188610A0 (en) Novel anti-allergic agents
DK1012175T3 (en) Peptide with affinity for coagulation factor VIII
DE60308994D1 (en) PROCESS FOR EXTRACTION, CLEANING AND ENZYMATIC CHANGING OF SOYA 7S GLOBULIN ALPHA 'SUBMERCH FOR USE AS HYPOCHOLESTEROL MIXER ACTIVE
BR0014634A (en) Wheat proteins and their use
JP2004505616A5 (en)
WO2005003162A3 (en) An endogenous peptide and active subfragments thereof